Beyond Meat’s shares fell on Thursday after McDonald’s acknowledged the end of its meatless burger trial in Canada. McDonald’s Corporation Yahoo Finance’s Heidi Chung joins The Final Round to break down the recent news surrounding McDonald’s and Beyond meat.
from Yahoo Finance https://ift.tt/3hXcENz
Yahoo Finance’s Akiko Fujita and Morningstar’s director for global ETF research Ben Johnson discuss the moves in cloud computing ETFs amid COVID-19.
from Yahoo Finance https://ift.tt/2VlplrP
The CEOs of major U.S. airlines, including American Airlines, Delta, JetBlue and Southwest, are meeting with Vice President Mike Pence to discuss the impact of COVID-19 on the industry. Yahoo Finance’s Akiko Fujita and Emily McCormick break down the details.
from Yahoo Finance https://ift.tt/2VoTPZM
Yahoo Finance’s Akiko Fujita and Morningstar’s director for global ETF research Ben Johnson discuss the moves in cloud computing ETFs amid COVID-19.
from Yahoo Finance https://ift.tt/2VlplrP
Spencer Rascoff, Co-founder and Fmr. Zillow CEO and dot.LA Founder, joins Yahoo Finance to discuss the trajectory for real estate across the U.S. and technological advancements in the field.
from Yahoo Finance https://ift.tt/383OhZO
Jules Trump, The Trump Group Co-Founder, joined The Final Round to discuss the state of the luxury real estate industry and how business has been since Florida’s reopening.
from Yahoo Finance https://ift.tt/2Zc67WA
Bess Freedman, Brown Harris Stevens CEO, joins Yahoo Finance to talk about demand in the housing market and what New York luxury real estate is like during COVID-19.
from Yahoo Finance https://ift.tt/3i9l6sT
Tobias Carlisle, Founder & Portfolio Manager at The Acquirers Fund, joins The Final Round to discuss his thoughts on the technology sector and whether it makes sense to invest into FAANG names amid such a volatile market.
from Yahoo Finance https://ift.tt/3g3nYpq
Are you looking to add a few blue chip ASX 200 shares to your portfolio in July? Then the three listed below could be worth considering.
I believe these blue chip shares have the potential to generate solid total returns for investors over the next few years. Here’s why I would buy them next month:
The first blue chip ASX 200 share I would consider buying in July is Coles. I think the supermarket giant would be a great option for a number of reasons. These include its defensive earnings, strong market position, and the refreshed strategy unveiled last year. This strategy aims to make $1 billion in cumulative savings by FY 2023 through the use of technology to automate manual tasks and simplifying above-store roles. I believe this leaves Coles well-positioned to achieve solid earnings and dividend growth over the next decade.
Another blue chip ASX 200 share to consider buying is Ramsay Health Care. Although the short term is likely to be challenging, I believe Ramsay’s long term growth potential remains very strong. This is because the company’s world class network of private hospitals looks set to benefit from the expected increase in demand for healthcare services in the future due to ageing populations and increased chronic disease. Another positive is Ramsay’s long history of making earnings accretive acquisitions. I believe there’s a strong chance it will acquire its way into new markets in the coming years to support its growth. Overall, I feel this puts it in a solid position to deliver strong total returns for investors over the 2020s and beyond.
A final blue chip ASX 200 share to consider buying is this job listings giant. As with Ramsay, SEEK is certainly having a tough time right now. But I don’t believe it will be long until trading conditions normalise and the company returns to growth. In respect to the latter, I believe its China-based Zhaopin business will be the key driver of growth in the future. This business has quickly become the pivotal part of the company and contributed 47.8% of its total revenue during the first half of FY 2020. Given how lucrative the China market is, I’m confident Zhaopin can underpin strong growth for SEEK for a long time to come.
3 “Double Down” Stocks To Ride The Bull Market
Motley Fool resident tech stock expert Dr. Anirban Mahanti has stumbled upon three under-the-radar stock picks he believes could be some of the greatest discoveries of his investing career.
He’s so confident in their future prospects that he has issued “double down” buy alerts on each of these three stocks to members of his Motley Fool Extreme Opportunities stock picking service.
*Extreme Opportunities returns as of June 5th 2020
More reading
Motley Fool contributor James Mickleboro owns shares of SEEK Limited. The Motley Fool Australia owns shares of COLESGROUP DEF SET. The Motley Fool Australia has recommended Ramsay Health Care Limited and SEEK Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post 3 of the best blue chip ASX 200 shares to buy in July appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2CPkNUh
With interest rates at ultra-low levels and looking likely to remain that way for the foreseeable future, I continue to believe investors would be better off putting any excess funds into the share market.
But where should you invest these funds? Here are three top shares I would invest $5,000 into in July:
The first share to look at is this goat’s milk-focused infant formula and baby food company. For a long time Bubs was delivering strong sales growth but posting significant losses. This led to the company burning through cash at a rapid rate and needing to tap the market for additional funds. Pleasingly, the company appears to have reached an inflection point and recently reported positive operating cashflow. I’m optimistic Bubs will build on this in the coming 12 months and start growing its earnings at a very strong rate.
Another option for a $5,000 investment could be PolyNovo. It is an exciting medical device company behind the NovoSorb technology. NovoSorb is a biodegradable material that can be used to aid the repair of bone fractures and damaged cartilage, and in skin grafts. The key product in its portfolio is the NovoSorb Biodegradable Temporising Matrix (BTM) product, which is a wound dressing intended to treat full-thickness wounds and burns. I believe this product, which was developed at CSIRO, is well-placed to capture a growing slice of a $1.5 billion market. And looking ahead, the company believes there is an opportunity to use NovoSorb in the hernia and breast treatment markets. Combined, these give PolyNovo a $7.5 billion addressable market.
A final share that I think could be worth considering is Pro Medicus. It is a healthcare technology company that provides radiology IT software and services. It has a number of products on offer, but the one that I’m most excited about is the Visage 7 Enterprise Imaging Platform. It delivers fast, multi-dimensional images which are streamed via an intelligent thin-client viewer. A number of major healthcare companies are using this platform, which I believe is a testament to its quality. In addition to this, management recently revealed that it has a number of sales opportunities in its pipeline that it is working on. If it can close these deals, it could underpin strong earnings growth over the coming years.
We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
More reading
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended BUBS AUST FPO and Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Where to invest $5,000 into ASX shares in July appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3dwIs8w